Home > Insider Trading > Filing (0001209191-14-034320)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1423824	Alder Biopharmaceuticals Inc	ALDR	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1270734	Deepika Pakianathan	C/O Delphi Ventures 3000 Sand Hill Rd., Bldg 1, Suite 135 Menlo Park CA 94025		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-05-13	2,463,894	$0.00	2,463,894	No	4	C	Indirect	By Delphi Ventures VII, L.P.
Common Stock	Acquisiton	2014-05-13	24,638	$0.00	2,488,532	No	4	C	Indirect	By Delphi BioInvestments VII, L.P.
Common Stock	Acquisiton	2014-05-13	346,535	$10.00	2,835,067	No	4	P	Indirect	By Delphi Ventures VII, L.P.
Common Stock	Acquisiton	2014-05-13	3,465	$10.00	2,838,532	No	4	P	Indirect	By Delphi BioInvestments VII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Delphi Ventures VII, L.P.
No	4	C	Indirect	By Delphi BioInvestments VII, L.P.
No	4	P	Indirect	By Delphi Ventures VII, L.P.
No	4	P	Indirect	By Delphi BioInvestments VII, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2014-05-13	2,083,541	$0.00	2,083,541	$0.00
Common Stock	Series D Preferred Stock	Disposition	2014-05-13	380,353	$0.00	380,353	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-05-13	20,835	$0.00	20,835	$0.00
Common Stock	Series D Preferred Stock	Disposition	2014-05-13	3,803	$0.00	3,803	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The preferred stock converted into common stock on a 1-for-1 basis upon the closing of the issuer's initial public offering and had no expiration date.
These securities are directly held by Delphi Ventures VII, L.P. ("DV VII"). Delphi Management Partners VII, L.L.C. ("DMP VII") is the general partner of DV VII and may be deemed to have sole voting and dispositive power over the securities held by DV VII. The Reporting Person is a managing member of DMP VII and may be deemed to share voting and dispositive power over the securities held by DV VII. The Reporting Person disclaims beneficial ownership of the securities held by DV VII, except to the extent of any pecuniary interest therein.
These securities are directly held by Delphi BioInvestments VII, L.P. ("DBI VII"). Delphi Management Partners VII, L.L.C. ("DMP VII") is the general partner of DBI VII and may be deemed to have sole voting and dispositive power over the securities held by DBI VII. The Reporting Person is a managing member of DMP VII and may be deemed to share voting and dispositive power over the securities held by DBI VII. The Reporting Person disclaims beneficial ownership of the securities held by DBI VII, except to the extent of any pecuniary interest therein.